Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.